Versor Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Versor Investments’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-433,471	Closed	-$1.65M	–	319
2020 Q1	$1.65M	Buy	433,471 +214,496	+98%	+$924K	0.11%	34
2019 Q4	$1.11M	Buy	+218,975	New	+$1.16M	0.06%	134

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Versor Investments's PGNX Position: Q2 2020 in Review

Versor Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 433,471 shares — an estimated $1.65M sold.

Versor Investments first reported a position in PGNX in Q4 2019 and held it in 2 quarters. The position peaked at $1.65M in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Versor Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Versor Investments sold 433,471 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.65M.
Versor Investments first reported a position in Progenics Pharmaceuticals Inc in Q4 2019 and held it in 2 quarters.
Versor Investments's Progenics Pharmaceuticals Inc position peaked at $1.65M in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Versor Investments's 13F filing for Q2 2020, filed 30 Jul 2020.